Search
Supernus Pharmaceuticals Inc
SUPNAdd to Watchlist
43.390USD
-0.360-0.82%
Close 09-23 16:00（ET）
2.52BMarket Cap
LossP/E TTM
Supernus Pharmaceuticals Inc (SUPN) Stock Price Target & Forecast
Analyst Rating
Based on 5 analysts giving stock ratings to Supernus Pharmaceuticals Inc in the past month.
Buy
1 Strong Buy
3 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
62.600USD+43.09%
SUPN Analyst Recommendation Trends
In the current month, SUPN has received 3 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. SUPN average Analyst price target in the last month is 62.600.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
1
1
2
2
2
2
2
2
3
3
3
3
3
3
3
3
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
5
6
6
6
6
6
6
SUPN Analyst Rating for Peer Comparison
Updated: Sep 23, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
7
17
12
1
0
37
Amgen Inc
AMGN
4
12
18
2
1
37
Eli Lilly and Co
LLY
10
17
6
1
0
34
AbbVie Inc
ABBV
8
19
6
0
0
33
Merck & Co Inc
MRK
8
14
10
0
0
32
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Vertex Pharmaceuticals Inc
VRTX
9
16
5
0
1
31
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Alnylam Pharmaceuticals Inc
ALNY
5
18
7
0
0
30
Regeneron Pharmaceuticals Inc
REGN
6
14
10
0
0
30
Financial Forecasting
Based on analysts' estimates, SUPN EPS is projected to reach 0.615 in FY2026Q3, following reported EPS of -1.005 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
0.34
0.30
0.36
0.61
1.08
Actual
-0.07
-0.04
-1.01
--
--
Surprise
-121.03%
-113.37%
-382.35%
--
--
FAQs
What is Supernus Pharmaceuticals Inc's expected revenue for the next quarter?
Supernus Pharmaceuticals Inc's expected revenue is 217.92M.
What is Supernus Pharmaceuticals Inc's price target?
Analysts forecast that Supernus Pharmaceuticals Inc's price target is USD 62.60, with the highest forecast at USD 67.00 and the lowest forecast at USD 55.00.
How have Supernus Pharmaceuticals IncSUPN's recent earnings per share performed?
The market expectation was USD -1.01, while Supernus Pharmaceuticals IncSUPN's earnings per share (EPS) for the previous quarter was USD -0.04. EPS for the next quarter is expected at USD 0.61.
What is the analyst rating for Supernus Pharmaceuticals Inc?
Based on the ratings of Supernus Pharmaceuticals Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.